Generic Relistor Availability

Relistor is a brand name of methylnaltrexone, approved by the FDA in the following formulation(s):

RELISTOR (methylnaltrexone bromide - injectable; subcutaneous)

  • Manufacturer: SALIX PHARMS
    Approval date: April 24, 2008
    Strength(s): 12MG/0.6ML (12MG/0.6ML) [RLD]
  • Manufacturer: SALIX PHARMS
    Approval date: September 27, 2010
    Strength(s): 8MG/0.4ML

RELISTOR (methylnaltrexone bromide - solution; subcutaneous)

  • Manufacturer: SALIX PHARMS
    Approval date: April 24, 2008
    Strength(s): 12MG/0.6ML (12MG/0.6ML) [RLD]

Has a generic version of Relistor been approved?

No. There is currently no therapeutically equivalent version of Relistor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relistor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
    Patent 6,559,158
    Issued: May 6, 2003
    Inventor(s): Joseph F.; Foss & Michael F.; Roizen & Jonathan; Moss & Chun-Su; Yuan & William; Drell
    Assignee(s): UR Labs, Inc. The University of Chicago
    A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Patent expiration dates:
    • November 3, 2017
      ✓ 
      Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION
  • Peripheral opioid receptor antagonists and uses thereof
    Patent 8,247,425
    Issued: August 21, 2012
    Inventor(s): Bazhina; Nataliya & Donato, III; George Joseph & Fabian; Steven R. & Lokhnauth; John & Megati; Sreenivasulu & Melucci; Charles & Ofslager; Christian & Patel; Niketa & Radebaugh; Galen & Shah; Syed M. & Szeliga; Jan & Zhang; Huyi & Zhu; Tianmin
    Assignee(s): Wyeth
    The present invention provides a compound of formula I: wherein X−, R1, and R2 are as defined herein, and compositions thereof.
    Patent expiration dates:
    • December 31, 2030
      ✓ 
      Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION
  • Peripheral opioid receptor antagonists and uses thereof
    Patent 8,420,663
    Issued: April 16, 2013
    Assignee(s): Wyeth
    The present invention provides a compound of formula I: wherein X−, R1, and R2 are as defined herein, and compositions thereof.
    Patent expiration dates:
    • September 30, 2029
      ✓ 
      Patent use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 24, 2013 - NEW CHEMICAL ENTITY

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Trouble with Ulcerative Colitis? Learn about treatments to alleviate symptoms. Click Here

Close
(web5)